Clinical Trial Update: Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating SAM-315 for Alzheimer's disease was terminated; the trial assessed safety, tolerability, pharmacokinetics and pharmacodynamics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SAM-315

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease | Phase 1 | Status: TERMINATED